![Banseog [ biohealth ]](/assets/brand/banseog-biohealth-on-dark.svg?v=20261015){kind=small}
An active pharmaceutical ingredient (API) company that makes APIs, led by cephalosporin antibiotics, for export to about 40 countries and runs CDMO work in mRNA materials, peptides and PEG.
Next-generation 5′ capping materials (Cap 1 analogs) for mRNA therapeutics and vaccines, including HanmiCap AG, 07 and 13; supplied together with the modified NTPs PUL and MUL from early research through commercial-stage GMP production.
Cephalosporin antibiotic APIs, the company's core field; it also offers CDMO and CMO for various cephalosporins and holds cGMP certifications from the U.S., the U.K., Germany, Australia and Japan, among others.
Runs domestic and overseas CDMO projects from preclinical process and analytical method development through GMP production of clinical samples and regulatory documentation.
Operates peptide production equipment in Building C and offers peptide CDMO, including PEG-peptide conjugation, aimed at the peptide demand driven by GLP-1 medicines.
Took part in BIO International Convention 2026 in San Diego, holding overseas business meetings centred on peptide CDMO and its HanmiCap mRNA materials.
A consortium led by iBiz Software was finally selected under the Ministry of Trade and Industry's 2026 manufacturing tacit-knowledge AI model programme for an API-plant AI process optimisation and early quality-detection project; the company provides its actual GMP manufacturing site, batch data and real-batch validation environment.
Official role guide
Observed 2026-10-26
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.